CBCC Global Research

CBCC Global Research, based in the US, is a comprehensive Clinical Research Organization (CRO) that specializes in delivering tailored clinical trial services across various therapeutic areas such as oncology and dermatology. Founded in 1984 and headquartered in Bakersfield, US, CBCC Global Research operates as a full-service Clinical Research Organization (CRO). The company has maintained its focus on providing specialized clinical research services without significant changes in its business strategy. It serves pharmaceutical and biotechnology sectors and has executed 1 deal as of May 27, 2025.

CBCC Global operates as a full-service Clinical Research Organization (CRO) with a focus on providing comprehensive clinical trial services tailored for various therapeutic areas, including oncology, ophthalmology, neuro-psychiatry, rare diseases, and dermatology. The company offers an array of services including Phase I-IV clinical trials, 505(b)(2) clinical development programs, core lab services, and writing services for regulatory and scientific documentation. By leveraging a network of over 400 sites, CBCC Global delivers solutions aimed at optimizing clinical research efficiency and ensuring quality compliance throughout the trial process. The company's clientele encompasses pharmaceutical and biotechnology companies, as well as academic institutions in need of reliable clinical trial management across diverse geographical markets, notably in the USA and India.

CBCC Global generates revenue through service contracts with clients in the pharmaceutical and biotechnology sectors, engaging in B2B transactions for its clinical trial services. The firm typically structures its transactions on a project basis, where clients agree to specific terms for services rendered throughout the duration of clinical trials. Pricing structures vary depending on the complexity and scale of the trial, with clients investing in multiple service offerings such as clinical trial management and regulatory writing services. Notably, flagship services include Phase I-IV clinical trials and specialized writing services that are critical for regulatory submissions.

The company’s revenue model is built around delivering high-quality clinical research while ensuring timely compliance with industry standards. In May 2025, Edgewater Capital Partners recapitalized CBCC Global Research. The rationale behind this acquisition is to support the company's growth. The specific details of upcoming new products or expansion plans have not been disclosed.